Methylphenidate /kg
Phase 3Small molecule
Methylphenidate /kg is one of 36 small molecule programs targeting Attention Deficit Hyperactivity Disorder. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
34 competitors in Attention Deficit Hyperactivity Disorder
#DrugCompanyPhaseTrials
1Ritalin
NovartisApproved
Strattera
MMap77
Approved
Vyvanse
TakedaApproved
Revia
TevaApproved
Nicorette
PfizerApproved
Intuniv
PPromius Pharma, LLC
Approved
Rocaltrol
Jazz PharmaceuticalsApproved
Northera
LundbeckApproved
Buspar
Bristol-Myers SquibbApproved
Brintellix
TakedaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Methylphenidate /kg. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- FFlorida International University